NasdaqGS - Delayed Quote • USD
Precigen, Inc. (PGEN)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:37 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.09 | -0.08 | -0.34 | -0.27 |
| Low Estimate | -0.09 | -0.09 | -0.37 | -0.42 |
| High Estimate | -0.08 | -0.06 | -0.27 | -0.13 |
| Year Ago EPS | -0.1 | -0.08 | -0.39 | -0.34 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 1.48M | 1.48M | 5.52M | 38.45M |
| Low Estimate | -- | -- | -- | 7M |
| High Estimate | 2.5M | 2.5M | 10M | 104.93M |
| Year Ago Sales | 1.85M | 1.77M | 6.22M | 5.52M |
| Sales Growth (year/est) | -20.00% | -16.20% | -11.30% | 596.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.09 | -0.1 | -0.08 | -0.08 |
| EPS Actual | -0.1 | -0.08 | -0.08 | -0.13 |
| Difference | -0.01 | 0.02 | 0 | -0.05 |
| Surprise % | -11.10% | 20.00% | 0.00% | -62.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.09 | -0.08 | -0.34 | -0.27 |
| 7 Days Ago | -0.09 | -0.08 | -0.34 | -0.27 |
| 30 Days Ago | -0.09 | -0.08 | -0.34 | -0.27 |
| 60 Days Ago | -0.07 | -0.07 | -0.31 | -0.19 |
| 90 Days Ago | -0.07 | -0.07 | -0.31 | -0.19 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PGEN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 10.00% | -- | -- | 6.50% |
| Next Qtr. | 0.00% | -- | -- | 12.00% |
| Current Year | 12.80% | -- | -- | 5.30% |
| Next Year | 20.60% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 2.40% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | JP Morgan: Neutral to Underweight | 3/22/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 3/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/10/2023 |
| Reiterates | JMP Securities: Market Outperform | 6/5/2023 |
| Initiated | JP Morgan: Neutral | 5/23/2023 |
Related Tickers
TCRT Alaunos Therapeutics, Inc.
1.3200
+13.79%
HALO Halozyme Therapeutics, Inc.
38.57
+0.29%
TOVX Theriva Biologics, Inc.
0.4195
+2.33%
RNAC Cartesian Therapeutics, Inc.
21.03
+0.62%
RIGL Rigel Pharmaceuticals, Inc.
1.1000
0.00%
TCRX TScan Therapeutics, Inc.
7.32
+0.41%
PSTX Poseida Therapeutics, Inc.
2.1300
+3.90%
ANAB AnaptysBio, Inc.
21.00
+11.29%
PRAX Praxis Precision Medicines, Inc.
54.80
+3.63%
NXTC NextCure, Inc.
1.3500
+4.65%